Katherine Janeway

Katherine Janeway, MD, MMSc is an Associate Professor of Pediatrics at Harvard Medical School and serves as Senior Physician at Dana-Farber/Boston Children's Cancer and Blood Disorders Center. She also directs Clinical Genomics at Dana-Farber Cancer Institute. With extensive training including medical school at Harvard, residency in Pediatrics at Boston Combined Residency Program, and fellowship in Pediatric Hematology-Oncology at Boston Children's Hospital and Dana-Farber Cancer Institute, Dr. Janeway has established herself as a leading expert in pediatric bone tumors and cancer genomics.

• Senior Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
• Director of Clinical Genomics, Dana-Farber Cancer Institute
• Associate Professor of Pediatrics, Harvard Medical School

Dr. Janeway's research focuses on pediatric sarcomas, particularly Ewing sarcoma and osteosarcoma. Her work spans the spectrum from basic molecular characterization to clinical trial design and implementation. She has made significant contributions to understanding the genomic landscape of pediatric solid tumors, developing precision medicine approaches, and addressing health disparities in pediatric cancer outcomes. Her research integrates genomics, clinical data, and patient-reported outcomes to improve treatment strategies and survival for children with cancer.

Analysis of Dr. Janeway's recent publications reveals a strong emphasis on precision oncology in pediatric cancers, with particular focus on Ewing sarcoma and osteosarcoma. Her work spans molecular characterization, clinical trial design, and implementation of genomic-guided therapies. The publications demonstrate growing integration of patient-reported outcomes, health equity considerations, and data-sharing initiatives in pediatric cancer research. Her leadership in Children's Oncology Group studies highlights her role in shaping the future of pediatric cancer treatment through collaborative, evidence-based approaches.

Dr. Janeway has served as principal or co-investigator on numerous clinical trials through the Children's Oncology Group, particularly in the Bone Tumor Committee. Her research has been supported by grants from the National Cancer Institute and other major funding organizations focused on advancing pediatric cancer care through genomic medicine and innovative clinical trial designs.

As Director of Clinical Genomics at Dana-Farber Cancer Institute, Dr. Janeway leads initiatives to integrate genomic medicine into clinical care for pediatric cancer patients. She is actively involved in the Pediatric MATCH trial and other precision medicine initiatives that match molecular alterations with targeted therapies for children with cancer.